Benitec Biopharma Debt to Equity Ratio 2014-2022 | BNTC

Current and historical debt to equity ratio values for Benitec Biopharma (BNTC) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Benitec Biopharma debt/equity for the three months ending September 30, 2022 was 0.03.
Benitec Biopharma Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-09-30 $0.00B $0.02B 0.24
2022-06-30 $0.00B $0.00B 1.07
2022-03-31 $0.00B $0.01B 0.34
2021-12-31 $0.00B $0.01B 0.29
2021-09-30 $0.00B $0.02B 0.15
2021-06-30 $0.00B $0.02B 0.07
2021-03-31 $0.00B $0.01B 0.23
2020-12-31 $0.00B $0.02B 0.06
2020-09-30 $0.00B $0.01B 0.15
2020-06-30 $0.00B $0.01B 0.13
2020-03-31 $0.00B 0.00
2019-12-31 $0.00B $0.02B 0.07
2019-09-30 $0.00B 0.00
2017-09-30 $0.00B $0.02B 0.09
2016-09-30 $0.00B $0.02B 0.05
2016-06-30 $0.00B $0.01B 0.06
2016-03-31 $0.00B $0.02B 0.09
2015-12-31 $0.00B $0.02B 0.04
2015-06-30 $0.00B $0.02B 0.07
2014-12-31 $0.00B $0.03B 0.02
2014-06-30 $0.00B $0.03B 0.03
2013-06-30 $0.00B $0.00B 1.75
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.006B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00